Technology
Health
Biotechnology

FibroGen

$44.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.46 (3.38%) Today
$0.00 (0.00%) As of 4:01 PM EDT after-hours

Why Robinhood?

You can buy or sell FibroGen and other stocks, options, ETFs, and crypto commission-free!

About FGEN

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Read More The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Employees
461
Headquarters
San Francisco, California
Founded
1993
Market Cap
3.88B
Price-Earnings Ratio
96.79
Dividend Yield
0.00
Average Volume
676.96K
High Today
$44.93
Low Today
$43.45
Open Price
$43.45
Volume
566.46K
52 Week High
$62.00
52 Week Low
$33.51

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2014 IPO
US
North America

FGEN News

ReutersAug 9

Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT

6

FGEN Earnings

-$0.67
-$0.03
$0.62
$1.26
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.51 per share
Actual
$1.26 per share

More FGEN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.